Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Scholar Rock Holding Corporation - Common Stock (NQ:SRRK)

55.88 +1.16 (+2.11%)
Streaming Delayed Price Updated: 2:27 PM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Scholar Rock Holding Corporation - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Scholar Rock to Present Data from TOPAZ Ambulatory Cohort Analysis at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present at Cowen’s 42nd Annual Health Care Conference
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present Biomarker Strategy for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit
From Scholar Rock
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to... 
Via Benzinga
News headline image
Scholar Rock Provides Corporate Update and Highlights Priorities for 2022
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Scholar Rock
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2021 ↗
Upgrades According to Loop Capital, the prior rating for Williams-Sonoma Inc (NYSE: 
Via Benzinga
News headline image
Scholar Rock Outlines Pivotal Apitegromab Trial Design In Spinal Muscular Atrophy Patients ↗
Scholar Rock Holding Corp (NASDAQ: SRRK) announced the study design for the SAPPHIRE Phase 3 trial of apitegromab, a selective inhibitor of the activation of latent... 
Via Benzinga
News headline image
Scholar Rock Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Presents Data from Part A of the DRAGON Phase 1 Trial Evaluating SRK-181 as Monotherapy and in Combination with Anti-PD-(L)1 for the Treatment of Solid Tumors -- Announces Advancement into Part B
From Scholar Rock
Via Business Wire
News headline image
48 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares jumped 68% to $9.04. Shares of mask and protective apparel companies, including Allied Healthcare Products, traded... 
Via Benzinga
News headline image
Scholar Rock Reports Third Quarter 2021 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
News headline image
Scholar Rock to Present at Upcoming Healthcare Conferences
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Pharmacologic Data at the 2021 World Congress of Neurology
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Presents Exploratory Responder Analysis on Efficacy Data from the Apitegromab TOPAZ Phase 2 Trial at the Child Neurology Society Annual Meeting
From Scholar Rock
Via Business Wire
News headline image
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
News headline image
Scholar Rock Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGFβ1 Activation
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present at the 2021 Cantor Virtual Global Healthcare Conference
From Scholar Rock
Via Business Wire
News headline image
48 Biggest Movers From Yesterday ↗
Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 data of its monoclonal antibody in hospitalized... 
Via Benzinga
News headline image
Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Reports Second Quarter 2021 Financial Results and Highlights Business Progress
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present at the 2021 Wedbush PacGrow Healthcare Conference
From Scholar Rock
Via Business Wire
News headline image
99 Biggest Movers From Yesterday ↗
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Arcturus Therapeutics (NASDAQ:ARCT) stock moved upwards by 29.05% to $44.73 during Tuesday's regular session. As of 12:35 EST, Arcturus Therapeutics's... 
Via Benzinga
News headline image
Scholar Rock Announces Leadership Change
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress
From Scholar Rock
Via Business Wire
News headline image
Scholar Rock Presents TOPAZ Phase 2 Data Showing the Transformative Potential of Apitegromab in Patients with Type 2 and 3 Spinal Muscular Atrophy (SMA) at the 2021 Virtual SMA Research & Clinical Care Meeting
From Scholar Rock
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.